Skip to main content
. 2018 Aug 14;11:4877–4891. doi: 10.2147/OTT.S169823

Figure 8.

Figure 8

Summary of lncRNAs with altered expression, potential targets and pathways entered in this study.

Abbreviations: AFAP1-AS1, AFAP1 antisense RNA 1; ANRIL, CDKN2B antisense RNA 1; CASC15, cancer susceptibility 15; CCAT2, colon cancer associated transcript 2; EMT, epithelial–mesenchymal transition; GAPLINC, gastric adenocarcinoma associated, positive CD44 regulator, long intergenic noncoding RNA; H19, H19, imprinted maternally expressed transcript; HOTAIR, HOX transcript antisense RNA; HOTTIP, HOXA distal transcript antisense RNA; LINC00673, long intergenic non-protein coding RNA 673; lncRNA, long noncoding RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MEG3, maternally expressed 3; PANDAR, promoter of CDKN1A antisense DNA damage activated RNA; PVT1, Pvt1 oncogene; Sox2ot, SOX2 overlapping transcript; SPRY4-IT1, SPRY4 intronic transcript 1; UCA1, urothelial cancer associated 1; XIST, X inactive specific transcript; ZEB1-AS1, ZEB1 antisense RNA 1; ZFAS1, ZNFX1 antisense RNA 1.